The synergy of β amyloid 1-42 and oxidative stress in the development of Alzheimer’s disease-like neurodegeneration of hippocampal cells

Gohar Karapetyan1, Katarine Fereshetyan1,2, Hayk Harutyunyan1 & Konstantin Yenkoyan1,2

Alzheimer’s disease (AD) is a type of dementia that affects memory, thinking and behavior. Symptoms eventually become severe enough to interfere with daily tasks. Understanding the etiology and pathogenesis of AD is necessary for the development of strategies for AD prevention and/or treatment, and modeling of this pathology is an important step in achieving this goal. β-amyloid peptide (Aβ) injection is a widely used approach for modeling AD. Nevertheless, it has been reported that the model constructed by injection of Aβ in combination with a prooxidant cocktail (ferrous sulfate, Aβ, and buthionine sulfoximine (BSO) (FAB)) best reflects the natural development of this disease. The relationship between oxidative stress and Aβ deposition and their respective roles in Aβ-induced pathology in different animal models of AD have been thoroughly investigated. In the current paper, we compared the effects of Aβ 1-42 alone with that of Aβ-associated oxidative stress induced by the FAB cocktail on the neurodegeneration of hippocampal cells in vitro. We constructed a FAB-induced AD model using rat primary hippocampal cells and analyzed the contribution of each compound. The study mainly focused on the prooxidant aspects of AD pathogenesis. Moreover, cellular bioenergetics was assessed and routine metabolic tests were performed to determine the usefulness of this model. The data clearly show that aggregated Aβ1-42 alone is significantly less toxic to hippocampal cells. Aggregated Aβ damages neurons, and glial cells proliferate to remove Aβ from the hippocampus. External prooxidant agents (Fe2+) or inhibition of internal antioxidant defense by BSO has more toxic effects on hippocampal cells than aggregated Aβ alone. Moreover, hippocampal cells fight against Aβ-induced damage more effectively than against oxidative damage. However, the combination of Aβ with external oxidative damage and inhibition of internal antioxidant defense is even more toxic, impairs cellular defense systems, and may mimic the late phase of AD-associated cell damage. Our findings strongly indicate a critical role for the combination of Aβ and oxidative stress in the development of neurodegeneration in vitro.
Oxidative stress in AD brain is manifested by decreased levels of antioxidant enzymes and also by increased protein oxidation (including protein carbonyls formation), lipid peroxidation, DNA oxidation, advanced glycation end products. Mitochondria are the main consumers of oxygen and the main organelles responsible for the formation of ROS. ROS generation involves the spontaneous leakage of electrons from respiratory chain complexes and direct interaction of these electrons with oxygen molecules. ROS attack proteins, lipids and nucleic acids, increasing the levels of end-products, such as protein carbonyls, thiobarbituric acid-reactive substances (TBARS), and malondialdehyde. Additionally, mitochondria are unique organelles that provide ATP to the host cell by oxidative phosphorylation. Neurons are highly differentiated cells that require a high level of ATP to maintain an ionic gradient and generate potentials, as well as for neurotransmission. Unlike other organs, the brain does not store excess ATP; thus, normal mitochondrial function is extremely important for the continuous generation and delivery of energy.

In addition, neuronal cells are more vulnerable to ROS due to the high rate of oxygen consumption and the enrichment of polyunsaturated fatty acids in membranes. Moreover, the level of redox metal ions is higher and the activity of the antioxidant system is lower in the brain than in other tissues. There is a growing body of evidence showing the presence of markers of oxidative stress in neurofibrillary tangles and senile plaques (SPs) in AD brain. Several studies indicated significant elevation of membrane PUFAs peroxidation by-product 4-hydroxynonenal (HNE) in hippocampus, amygdala, temporal cortex and cerebrospinal fluid of AD cases. HNE neurotoxic mechanisms may be mediated by modifying neuron membrane proteins/enzymes, altered glucose and glutamate transport system, calcium metabolism, etc. This indicates that, in line with the primary damaging effect of reactive oxygen species on neuron membrane, a secondary, reaction by-products are capable of increasing neuron degeneration. Additionally, the level of antioxidant enzyme glutathione S-transferases (GST) is significantly decreased in AD brain, consistent with the notion that a loss of protection against HNE might be correlated with subsequent neuronal death. In fact, it is known that Aβ decreases activity of mitochondrial superoxide dismutase, which detoxifies the anion superoxide and protects from peroxidative damage. Aβ is also capable of binding and inhibiting mitochondrial alcohol dehydrogenase known as ABAD (Aβ binding alcoholdehydrogenase). ABAD has a protective role, being responsible for the detoxification from aldehydes such as 4-hydroxynonenal. In addition, several studies have reported that Aβ affects mitochondrial DNA and proteins, leading to impairment of the electron transport chain and ultimately mitochondrial dysfunction. In turn, it should be noted that mitochondrial dysfunction causes alterations in amyloid precursor protein (APP) metabolism, enhances intraneuronal accumulation of Aβ and makes neuronal cells vulnerable. Undoubtedly, the generation of ROS and accumulation of Aβ peptides are interconnected. It is important to note that alterations in the AD brain, such as the presence of redox metal ions, mitochondrial dysfunction, and an imbalance of antioxidant/oxidant enzymes, also induce ROS production.

However, the importance of Aβ-associated oxidative stress for neurodegeneration relative to that of other forms of AD-associated oxidative stress still needs to be investigated.

Thus, in the current study, the combination of ferrous sulfate, Aβ1-42, and buthionine sulfoximine (BSO) (FAB) was chosen to recapitulate AD pathophysiology as closely as possible. Aβ1-42 is more amyloidogenic than other Aβ peptides due to its hydrophobic characteristics. Ferrous sulfate was used as a prooxidant factor to induce oxidative stress under conditions of glutathione synthase inhibition. Glutathione synthase is an important enzyme in the antioxidant system, and inhibition of this enzyme by BSO likely contributes significantly to AD pathogenesis. Several studies have shown that administration of the FAB cocktail into the intraventricular system by a pump over 4 weeks can be used to successfully model AD in rats. In the current study, the FAB cocktail was administered to primary rat hippocampal cells. We cultivated mixed cells isolated from the rat hippocampus, which included both glial and neuronal cells. This allowed us to recapitulate the complex environment of the brain, including neuroglial interactions, which play a very important role in AD pathogenesis. This cellular model of AD allowed us to monitor dynamic metabolic changes over several days. This study mainly focused on the prooxidant aspects of AD pathogenesis. Furthermore, cellular bioenergetics was assessed and routine metabolic tests were performed to evaluated cell survival and viability.

Materials and methods

Study material and experimental design. All animal experiments were approved by the local institutional committee of Animal Welfare and performed in accordance with international law regarding the protection of animals and the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 8th Edition, 2011) and in compliance with the ARRIVE guidelines for animals. Experiments were carried out on primary hippocampal cells obtained from adult rats. The cells were obtained from six hippocampal samples (from 3 animals) and divided into eight groups, with 5 wells for each group. The cells in groups 2–8 were treated with various agents that cause neuronal damage. Specifically, group 2 was treated with aggregated Aβ (Aβ1-42) at a final concentration of 5 μM, group 3 was treated with BSO at a final concentration of 4 mM, group 4 was treated with iron sulfate (Fe) at a final concentration of 0.33 mM, group 5 was treated with Fe + Aβ, group 6 was treated with BSO + Aβ, group 7 was treated with Fe + Aβ, and group 8 was treated with BSO + Fe + Aβ. Group 1 served as the control group. All chemicals were obtained from Sigma (Sigma, USA) and were of the highest purity available.

Cell culture. Primary hippocampal cells were isolated from the brains of two-month-old rats (100–150 g, female) as described previously. Briefly, the animals were decapitated after being euthanized with CO2. The brains were isolated, and then the hippocampus was immediately excised from the thalamus and dissociated using syringes with decreasing needle diameters. We obtained 0.2–0.4×10⁶ cells from each hippocampal sample. The hippocampal cells were cultured in NeuroCult neural cell culture medium (STEMCELL
Cell microscopy and immunofluorescence assay. Live cell imaging and fluorescence microscopy were performed using an EVOS FL Cell Imaging System (Thermo Fisher Scientific, USA). Phase-contrast microscopy was applied to count unstained live cells and evaluate morphology. Immunofluorescence was performed on cells on 1.5 coverslips according to a previously described protocol24. Cells were plated on coverslips in culture dishes and cultured for 14 days (at 37 °C in 5% CO2 in a humidified incubator). The cells were fixed at the respective time points with 4% paraformaldehyde (PFA) for 15 min and then washed once with 200 µl of PBS (0.1 M, pH 7.4) for 5 min. The liquid was removed by a suction pump throughout the procedure. The cells in the six-well plates were washed three times for 5 min each with 1.5 ml of PBST (0.3% Triton X-100 in PBS). The fixed cells were preblocked with 1.5 ml blocking buffer (1% BSA, 4% normal goat serum, 0.3% Triton X-100 in PBS) for 1 h at RT. After blocking, 1.5 ml of primary antibody (glial fibrillary acidic protein (GFAP) or neuronal nuclei (NeuN), 1:1000) diluted in blocking buffer was added to each well. The plates were then incubated on a shaker at 100 rpm and 4 °C for at least 18 h. After incubation with primary antibody, the buffer was removed, and the cells were washed 3 × 10 min with 1.5 ml of PBST. Secondary antibody (Alexa Fluor 568-conjugated goat-anti-rabbit and Alexa Fluor 488-conjugated goat-anti-mouse, diluted 1:1000 in blocking buffer) was added to the wells. The cells were incubated for at least 1.5 h at RT. The plates were covered with aluminum foil to protect them from light. After incubation with secondary antibody, the coverslips were washed for 10 min in 1.5 ml of PBST and then washed twice for 10 min with 1.5 ml of PBS. The coverslips were held with fine forceps and dipped into 50 ml Falcon tubes containing Milli-Q H2O to rinse off the PBS. The nuclei were stained using DAPI. Before mounting, the coverslips were gently dried by touching the edge with tissue paper. The coverslips were mounted on Superfrost slides with 10 µl of mounting media. The slides were stored in the dark at 4 °C and protected from light until imaging. After immunohistochemistry, GFAP+/DAPI−, GFAP+/DAPI−, and GFAP+/NeuN+ cells were counted.

Biochemical tests. The levels of molecules reflecting cellular metabolism (glucose and lactate levels) and cell damage (lactate dehydrogenase (LDH) levels) in the medium were measured using Roche Cobas C311 and Cobas E411 automatic biochemical analyzers (Roche Cobas, Switzerland) and appropriate test kits. Protein carbonylation, advanced oxidation protein products (AOPP), and TBARS levels in the culture medium were measured to assess oxidative stress levels in the cultured cells. All spectrophotometric measurements were performed using a Thermo Scientific™ Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher Scientific, USA). Biochemical tests were performed on 3, 7, 14, and 21 days of culture.

Measurement of bioenergetics parameters. We seeded 0.25 × 106 cells/ml in 80 µl of culture medium in each well of an XF HS Mini cell culture microplate (Seahorse Bioscience, Billerica, MA, USA) and incubated them overnight at 37 °C in 5% CO2. The culture medium was replaced with 180 µl of bicarbonate-free DMEM supplemented with 10 mM glucose, 1 mM pyruvate and 2 mM l-glutamine (pH 7.4). The cells were incubated at 37 °C for 30 min before measurement. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using an XF HS Mini Extracellular Flux Analyzer. The following inhibitors were used at the indicated concentrations: 1.5 µM oligomycin, 2 µM FCCP, and 0.5 µM rotenone and antimycin A. Analyses were conducted using Wave software and XF Report Generators (Agilent Technologies). The sensor cartridge for
the XFe analyzer was hydrated at 37 °C 1 day before the experiment. The OCR and ECAR were normalized to the total amount of protein. Three wells from each group were analyzed, and the average was obtained.

**Data analysis.** Data analysis was carried out with GraphPad InStat software Version 3.10 (GraphPad Software, San Diego, CA). Unpaired *t* test was used to compare the levels of biomarkers between groups (*n* = 5). The normality of the data was assessed by the Kolmogorov–Smirnov test. The means, standard deviations (SDs) and associated *P* values are reported. *Ps* < 0.05 indicated statistical significance.

**Institutional review board statement.** The experimental protocol was performed in accordance with the guidelines of the European Communities Council Directive (86/609/EEC) and was approved by the Ethics Committee of Yerevan State Medical University after Mkhitar Heratsi (Identification code N 4–2/18. Date: 15 November 2018).

**Results**

**Cell number and morphology.** Hippocampal cells growth in primary culture (control cells) was characterized by a short lag phase during the first 7 days followed by a moderate increase in cell number (by 27.2%) until the 14th day of cultivation (exponential phase). The last 7 days of culture (14–21 days) was a stationary phase, during which we did not observe cell growth (Fig. 1A). The changes in neuronal morphology were evaluated using phase-contrast microscopy. Until the 7th day of culture, hippocampal cells appeared as round cells (Fig. 1B). After 7 days of culture, the hippocampal neurons extended moderate-sized apical dendrites, and early branches began to grow (Fig. 1C). On the 21st day of cultivation, although no proliferation was observed, extended axons and dendrites were observed (Fig. 1D).

Aggregated Aβ (1-42) had a marked effect on neuronal cell growth in the exponential phase (7–14 days) of growth in culture; on the 7th day of culture, the cell count in the Aβ group was 51% lower (*P* < 0.05) than that...
in the control group. After this point, cells in the Aβ group retained moderate proliferative capability, and the increase in cell number in this group in the exponential phase (from the 7th to 14th days of culture) was 21% (Fig. 1A). This growth rate was not significantly different from that in the control group (P > 0.05). The other experimental groups exhibited more pronounced cell loss and no proliferation. The cell count in these groups in the lag phase was markedly decreased, and no exponential growth phase was observed. The combination of BSO or Fe and Aβ decreased the cell count by 82% and 84%, respectively (P < 0.05). The combination of all compounds (Aβ, BSO, Fe2+) in one plate (the FAB model) had in much more detrimental effects. The cell number in the FAB group was only 6.5% of that in the control group (P < 0.05).

Immunocytochemistry. In the current study, we did not purify neuronal cells but analyzed the effect of FAB on mixed hippocampal cells in culture. Therefore, in the first immunocytochemistry study, we mainly focused on hippocampal astroglia. To this end, we stained cells with an anti-GFAP antibody and DAPI. Immunocytochemistry was performed on the 14th day of cultivation in the exponential growth phase. We calculated the GFAP+/DAPI−/GFAP+ ratio, which was 1.67 ± 0.34 in the control group (Fig. 2A, Q). This ratio was markedly increased in the cells treated with Aβ (Fig. 2B, F, Q); the GFAP+/DAPI−/GFAP+ ratio was 4.57 ± 0.68 in the Aβ group and 2.50 ± 0.73 in the BSO + Aβ group (P < 0.05). In these groups, the cells retained the ability to form axons and dendrites. The number of GFAP+ cells in the Fe2+-treated groups was decreased, and the GFAP+/DAPI−/GFAP+ ratio was 0.78 ± 0.26 in the Fe group and 0.56 ± 0.22 in the BSO + Fe group (P < 0.05) (Fig. 2D, E, Q). Although the GFAP+/DAPI−/GFAP+ ratio was normal in the BSO group (1.39 ± 0.41; P > 0.05), cells in this group exhibited diminished axon and dendrite formation (Fig. 2C, Q). GFAP+/DAPI−/GFAP+ ratio in the remaining groups was not significantly differ from the control samples (Fig. 2G, H, Q).

In the next immunocytochemistry study, hippocampal cells were stained for GFAP and NeuN. The GFAP+/NeuN− ratio in control samples was 0.69 ± 0.17 on the 14th day of cultivation (Fig. 2I, R). Similar to the data reported above, the GFAP/NeuN ratio was significantly increased in Aβ and BSO + Aβ samples (3.83 ± 0.87 and 3.75 ± 0.76, respectively) (P < 0.05) (Fig. 2J, N, R). The GFAP/NeuN ratio in the other groups did not differ significantly from that in the control group (Fig. 2K–M, O–R).

Analysis of neuronal metabolism and survival via determination of glucose, lactate, and LDH levels. Glucose and lactate concentrations and LDH activity in the culture medium were measured to evaluate neuronal metabolism and damage, respectively (Fig. 3). We found that in the control samples, the glucose concentration gradually decreased until the 14th day of cultivation (Fig. 3A). The glucose content in the culture medium gradually decreased from 24.91 ± 0.52 to 21.03 ± 0.37 mmol/l in the control group. During the last week of cultivation (14–21 days of culture), the glucose concentration in the culture medium did not change significantly. The change in the glucose concentration was strongly correlated with the change in the cell
count presented above and reflects cell metabolism, which gradually decreased. Fe application almost completely abolished glucose utilization, likely by causing oxidative stress and cell death (Fig. 3A). In the Aβ-treated groups (the Aβ, Fe + Aβ, and BSO + Fe + Aβ groups), intermediate toxicity was observed. Glucose utilization was most markedly affected in the BSO + Fe + Aβ group but less affected in Aβ group (Fig. 3A). The change in glucose content in the culture medium was similar between the Aβ group and the control group. Interestingly, wave-like fluctuations in glucose concentrations were observed in the BSO-treated groups (the BSO, BSO + Fe, and BSO + Aβ groups). Generally, the change in glucose concentrations in these groups was similar to that in the Aβ-treated groups, but there were two periods in which glucose utilization was abolished, i.e., 3–7 day of culture and 14–21 days of culture (Fig. 3A).

The change in lactate accumulation in the neuronal cell medium was opposite of the change in glucose concentrations, which is expected and normal for metabolically active cells. In the control group, we observed lactate accumulation until the 7th day of culture, when the analyte concentration reached 4.51 ± 0.49 mmol/l (Fig. 3B). The lactate concentration in the control group gradually decreased after the 7th day and until the end of cultivation and finally reached a value of 3.84 ± 0.42 mmol/l. The change in lactate accumulation in the Aβ-treated groups (the Aβ, Fe + Aβ, and BSO + Fe + Aβ groups) resembled the change in glucose concentrations. The curves representing the change in the lactate concentration in these groups showed the same shape as the curve of the control group, but the concentrations were lower. Cells treated with Aβ alone showed less marked changes, with lactate concentrations reaching the maximal value (3.12 ± 0.27 mmol/l) on the 7th day of cultivation and gradually decreasing to 2.44 ± 0.35 mmol/l (Fig. 3B). In the BSO-treated groups (the BSO, BSO + Fe,
and BSO + Aβ groups), the lactate concentration reached the maximal value on the 3rd day of culture and then exhibited wave-like fluctuations until the 21st day of culture (Fig. 3B).

Intracellular LDH release indicates a change in cell membrane permeability and reflects the extent of damage. In our experiments, a gradual increase in LDH activity was observed in the control group until the 7th day of cultivation, with LDH activity peaking at 7.86 ± 0.48 IU/ml. Afterward, LDH activity gradually decreased, reaching a value of 6.03 ± 0.76 IU/ml at the end of cultivation (Fig. 3C). Overall, the change in LDH activity resembled the change in lactate levels and reflected cellular metabolism. The change in LDH activity in the Aβ-treated groups (the Aβ, Fe + Aβ, and BSO + Fe + Aβ groups) resembled the change in LDH activity in the control group, but LDH activity was much higher in the control group than in the other groups. The greatest degree of cellular damage was observed in the BSO + Fe + Aβ group, with LDH activity reaching 16.07 ± 1.93 IU/mL (P < 0.05) on the 7th day of cultivation (Fig. 3C). In the BSO-treated groups (the BSO, BSO + Fe, and BSO + Aβ groups), LDH activity was decreased on the 14th day of cultivation, which is consistent with the results of previous metabolic tests.

Oxidative modification of cellular proteins and lipids. To address the prooxidative capacity of Aβ and FAB, we measured several relevant parameters. On the 3rd day of culture, we measured protein carbonylation, lipid peroxidation (TBARS), and AOPP levels in the culture medium. The findings showed that Aβ significantly enhanced protein oxidative modification (Fig. 4A, C). In the Aβ group, the protein carbonylation level was 6.43 ± 0.94 nmol/ml and the AOPP concentration was 7.40 ± 0.89 nmol/ml, whereas in the control group, the protein carbonylation level and AOPP level were 4.02 ± 0.71 nmol/ml and 4.80 ± 1.07 nmol/ml, respectively (P < 0.05 versus the Aβ group). Further addition of BSO and BSO + Fe significantly increased oxidative damage to cellular proteins. The protein carbonylation level was 8.49 ± 1.21 nmol/ml and 9.98 ± 1.54 nmol/ml in the BSO + Aβ and BSO + Fe + Aβ groups, respectively (P < 0.05). The AOPP level was also significantly increased. In the BSO + Aβ and BSO + Fe + Aβ groups, the AOPP level was 10.00 ± 1.38 nmol/ml and 9.98 ± 0.79 nmol/ml, respectively (P < 0.05 versus the Aβ group). Interestingly, Fe + Aβ resulted in less protein oxidation than Fe alone (Fig. 4A, C). BSO induced less protein oxidation in hippocampal neurons than Aβ. Additionally, Fe and Aβ enhanced the prooxidant effects of BSO. Similar to Aβ + BSO, Fe + BSO resulted in less oxidation than Fe alone (Fig. 4A, C).

As stated above, the degree of lipid peroxidation was evaluated by measuring TBARS content in neuronal cell lysates. The TBARS content in control cell lysates was 5.10 ± 0.67 nmol/ml (Fig. 4B). Compared to protein oxidation (carbonylation and AOPP formation), Aβ did not significantly alter TBARS levels (5.33 ± 1.12 nmol/ml; P > 0.05). The same was not true for BSO, which significantly enhanced lipid peroxidation in neuronal cell lysates (6.97 ± 0.89 nmol/ml; P > 0.05). Aβ + BSO and BSO + Fe, but not Fe alone, significantly increased TBARS levels (Fig. 4B). Here, we also observed an unexpected decrease in lipid peroxidation in the BSO + Fe and Aβ + Fe groups compared with the Fe group (Fig. 4B).

Cellular bioenergetics analysis. To determine how Aβ, BSO, Fe, and their combination (FAB) affect cellular bioenergetics, we determined the OCR and ECAR by extracellular flux analysis. Cellular bioenergetics indicators were measured on the 3rd day of culture. The basal and ATP generation-coupled OCR and maximal respiration were significantly affected by Aβ and Fe (P < 0.05). However, the effect of BSO on OCR was negligible (Fig. 5A). BSO did not have a significant effect on the basal and ATP generation-coupled OCR (P > 0.05). Nevertheless, maximal respiration in the BSO group was almost 30% less (P < 0.05) than that in the control group. The Fe-treated groups exhibited the lowest basal OCR (Fig. 5C).
The ECAR showed the opposite change. Using extracellular flux analysis, we found that BSO and Fe markedly decreased the ECAR; however, the effect of Aβ on the ECAR was less obvious (Fig. 5B). The BSO- and Fe-treated groups exhibited the lowest basal ECAR (Fig. 5C).

The basal ECAR and OCR were plotted, and the results are shown in Fig. 2C. The data represent the change in the metabolic profile of the cells induced by Aβ, BSO, and Fe. The different effects of Aβ and BSO on cellular bioenergetics are shown. The Aβ-treated groups showed a more glycolytic profile, and a more aerobic profile was observed in the BSO-treated groups (Fig. 5D). Aβ and BSO exerted a synergistic effect, resulting in a less energetic cellular phenotype due to a decrease in both aerobic and glycolytic flux in the cell. Fe overload more markedly inhibited cellular bioenergetics (Fig. 5D).

Discussion
In the current study, we show for the first time the effect of Aβ and the components of FAB on growth parameters, oxidative damage, and bioenergetics parameters in adult rat mixed primary hippocampal cells. First, we characterized the changes in cell number and morphology in the control group. The control group exhibited a classical growth curve: a lag phase during the first 7 days, an exponential phase (7–14 days), and a stationary phase (14–21 days of culture). Most previous studies have focused on keeping adult neurons alive for a period of time (21 days)²⁵,²⁹,³⁰.

In the lag phase, hippocampal cells were round cells without outgrowths. In the exponential phase, hippocampal neurons exhibited moderate-sized apical dendrites, and early branches began to grow. In the stationary phase, despite loss of cell proliferation, extended axons and dendrites were observed. These data are in good accordance with previous reports²⁵.

Figure 5. Effect of Aβ, BSO, and Fe⁺ on bioenergetics parameters in hippocampal cells. (A) The OCR of cultured hippocampal cells on the 3rd day of culture. (B) The ECAR of cultured hippocampal cells on the 3rd day of culture. (C) Basal OCR and ECAR. (D) Metabolic profiles of hippocampal cells. Analyses were conducted using Wave software and XF Report Generators (Agilent Technologies).
Aggregated Aβ (Aβ1-42) had a marked effect on the changes in neuronal cell growth in the exponential phase. Aβ decreased the number of cells (by 51%) on the 7th day of culture. After this, cells in the Aβ group retained moderate proliferative capability. The other experimental groups exhibited more pronounced cell loss and no proliferation. The cell number in the lag phase was robustly decreased in these groups, and no exponential phase was observed. Aβ + BSO and Aβ + Fe decreased the cell number by 82% and 84%, respectively. The BSO + Fe + Aβ group (FAB model) showed maximum inhibitory/cytotoxic activity and resulted in much more detrimental/cytotoxic consequences.

The effect of Aβ on cultured hippocampal neurons was shown previously and can be explained by Aβ-mediated neuronal cell death resulting from the loss of full-length Tau and/or the generation of toxic fragments. The effect of chronic intracerebroventricular delivery of Aβ in combination with the prooxidant Fe2+ or the glutathione synthesis inhibitor BSO on brain histopathology and memory loss in adult rats was shown previously. The destructive effect of Aβ in combination with oxidative stress induced by BSO and Fe was most appropriately reflects AD-like symptomatology. However, there have been no studies on the effect of FAB in cultured neurons.

Using immunocytochemistry (with anti-GFAP and anti-NeuN antibodies), we assessed neuronal cell loss in the Aβ-treated groups and membrane damage/loss in the BSO- and Fe-treated groups. FAB caused total cell death. Our results were in good accordance with previous in vivo experiments.

We also showed the detrimental effect of Aβ and other FAB components on metabolism. It was found that glucose consumption and lactate production were inhibited. Interestingly, unique changes in the levels of glucose and lactate were observed in the BSO-treated groups. The maximal decrease in the levels of these metabolites was observed on the 7th day of culture, after which the changes were relatively similar to those in the control group. The detrimental effect of BSO can be explained by its ability to deplete glutathione, which causes apoptotic cell death. This phenomenon was not observed in the Aβ-treated groups and might have been due to the purification of BSO from the medium after replacement of irreversibly inhibited enzymes with new enzymes. This was not true for the Aβ-treated samples, probably because Aβ binds to cellular membranes, as presented earlier, this binding allows a constant Aβ concentration to maintained at all cultivation time points despite medium replacement.

We analyzed the prooxidant activity of the studied analytes and found an increase in lipid peroxidation in the BSO-treated groups (high TBARS level) and oxidative damage to proteins in the Aβ-treated groups (high levels of protein carbonylation and AOPP). These findings support in the immunocytochemistry results, indicating that the membrane was likely damaged or lost in the BSO-treated groups, and are consistent with the literature.

Finally, the difference in the effects of Aβ and BSO were assessed by extracellular flux analysis. We observed that Aβ inhibited of mitochondrial oxidative phosphorylation and that BSO inhibited glycolysis. The combination of these resulted in maximal alterations in cellular bioenergetics.

Our findings clearly show that aggregated Aβ1-42 alone is significantly less toxic to hippocampal cells. Aggregated Aβ damages neurons, and glial cells proliferate to remove Aβ from the hippocampus. External prooxidant agents (Fe2+) or inhibition of the internal antioxidant defense by BSO is more toxic to hippocampal cells than aggregated Aβ alone. Hippocampal cells fight against Aβ-induced damage more effectively than against oxidative damage. However, the combination of Aβ, external oxidative damage and inhibition of internal antioxidant defense is even more toxic, impairs cellular defense systems, and may represent the late phase of AD-associated cell damage.

Immunohistochemical analysis clearly indicated that Aβ targeted neuronal cells (NeuN positive). Glial cells proliferate and can remove toxic Aβ from the cellular environment. This explains why we observed and increase in the number of GFAP+ relative to NeuN+ cells. Aβ exerted prooxidant activity, as evidenced by increased protein carbonylation and AOPP levels. It is likely that Aβ-dependent oxidative damage might have been due to inhibition of mitochondrial oxidative phosphorylation by Aβ, which was observed in our experiments using extracellular flux analysis.

It seems that Aβ toxicity mechanism is based on ROS accumulation. All around ROS and metals with transparent valency. First of all, the whole Aβ molecule has some metal-binding sites in its first 15 amino acids constituted by the histidines 6, 13, and 14 and the tyrosine in the 10 position. These all have well-known and powerful metal-binding sites, and a nearby affinity to the best metallic chelants currently known. The Aβ possesses the ability to reduce Cu2+ and Fe3+ towards Cu+ and Fe2+, respectively. This way, the molecular oxygen can react with reduced metals thus generating superoxide anion, which in turn combines with two hydrogen atoms to form hydrogen peroxide that may later react with another reduced metallic ion and then forming the hydroxyl radical by Fenton reaction. The Aβ (in its radical form) can extract protons from the neighboring lipids or proteins, thus generating lipid peroxides and carbonyls, respectively. Above it, using data achieved by extracellular flux analysis, we clearly demonstrated Aβ induced mitochondrial dysfunction. The later can be considered as a next cause of ROS overproduction in neurons. Growing evidence suggests that Aβ has deleterious effects on mitochondrial function and contributes to energy failure, neuronal apoptosis and production of ROS in AD brain. However, in all probability, well-functioning antioxidant defense system of the organism is able to compensate prooxidant consequences of Aβ alone. Thus, as a real and powerful cause of Alzheimer’s disease-like neurodegeneration, we consider simultaneous damage of pro/antioxidant homeostasis with the accumulation of Aβ peptides in neuronal cell.

Conclusion
In conclusion, the results of this study show that the combination of aggregated Aβ, an antioxidant-depleting agent (BSO) and a prooxidant (Fe2+) (FAB) more completely recapitulates neuronal cell damage in vitro. This strongly indicates a critical role for the combination effect of Aβ and oxidative stress in the development of neurodegeneration.
Data availability
Data can be made available by the corresponding author upon reasonable request.

Received: 28 June 2022; Accepted: 19 October 2022
Published online: 25 October 2022

References
1. Cheng, X. S. et al. Neurite2 attenuates Tau phosphorylation through activation of PKP2. J. Alzheimer’s Dis. 36(1), 185–195. https://doi.org/10.3233/JAD-122173 (2013).
2. Ikonomovic, M. D. et al. Precocious amyloid burden is associated with reduced cholinergetic activity in Alzheimer disease. Neurology 77(1), 39–47. https://doi.org/10.1212/WNL.0b013e3182321419 (2011).
3. Nichols, E. et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18(1), 88–106. https://doi.org/10.1016/S1474-4422(18)30043-4 (2019).
4. Drummond, E. & Wisniewski, T. Alzheimer’s disease: Experimental models and reality. Acta Neuropathol. 133(2), 155. https://doi.org/10.1007/S00401-016-1662-X (2017).
5. LaFerla, F. M. & Green, K. N. Animal models of Alzheimer disease. Cold Spring Harbor Perspect. Med. 2, 11. https://doi.org/10.1101/CSPM.PERSPECT.006632-12 (2012).
6. Chen, X. Q. & Mobley, W. C. Alzheimer disease pathogenesis: Insights from molecular and cellular biology studies of oligomeric Aβ and Tau species. Front. Neurosci. 13, 1. https://doi.org/10.3389/FNINS.2019.00659 (2019).
7. Yana, M. H., Wang, X. & Zhu, X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 62, 90–101. https://doi.org/10.1016/J.FREERADBIOMED.2012.11.014 (2013).
8. Allan, B. D., Alessandra, C., Christopher, M. L. & Jennifer, D. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in alzheimer’s disease brain contribute to neuronal death. Aging (2013), 25–664 (2002).
9. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med. 23, 134–147. https://doi.org/10.1016/S0891-5849(96)00062-9 (1997).
10. Zhao, R. Z., Jiang, S., Zhang, L. & Yu, Z. B. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med. 44(1), 3–15. https://doi.org/10.3892/IJMM.2019.4188/HTML (2019).
11. Su, L. J. et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid. Med. Cell. Longev. https://doi.org/10.1155/2019/5080843 (2019).
12. Pathak, D. et al. The role of mitochondrially derived ATP in synaptic vesicle recycling. J. Biol. Chem. 290(37), 22325. https://doi.org/10.1074/JBC.M115.656045 (2015).
13. Kann, O. & Kovács, R. Mitochondria and neuronal activity. Am. J. Phys. Cell Physiol. 292(2), 641–657. https://doi.org/10.1152/ASPCP.00222.2006/ASSET/IMAGES/LARGE/ZH0002573970002.jpg (2007).
14. Salim, S. Oxidative stress and the central nervous system. J. Pharmacol. Exp. Ther. 360(1), 201. https://doi.org/10.1124/IPET.116.237503 (2017).
15. Wang, X. & Michaelis, E. K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2(1), 12. https://doi.org/10.3389/FNAGL.2010.00012/BIBTEXT (2010).
16. Cobley, J. N., Fiorello, M. L. & Bailey, D. M. 13 reasons why the brain is susceptible to oxidative stress. Am. J. Phys. Cell Physiol. 237503 (2017).
17. Butterfield, D. A., Reed, T., Newman, S. F. & Sultana, R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic. Biol. Med. 43(5), 658–677. https://doi.org/10.1016/J.FREERADBIOMED.2007.03.037 (2007).
18. Zuo, L., Hemmelgarn, B. T., Chiang, C. C. & Best, T. M. The role of oxidative stress-induced epigenetic alterations in amyloid-β production in alzheimer’s disease. Oxid. Med. Cell. Longev. https://doi.org/10.1155/2015/604658 (2015).
19. Sahu, M. P., Níkkiö, O., Lága, S., Kolehmainen, S. & Castrén, E. Culturing primary neurons from rat hippocampus and cortex. Neural Signal. 3, 2. https://doi.org/10.1038/NS20180207 (2019).
20. Seibenhener, M. L. & Wooten, M. W. Isolation and culture of hippocampal neurons from prenatal mice. J. Visual. Exp. doi.org/10.3791/3634 (2012).
21. Levine, R. L. et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186(1), 464–478. https://doi.org/10.1016/0076-6879(90)68141-H (1990).
22. Witko, V., Nguyen, A. T. & Descamps-Latscha, B. Microtiter plate assay for phagocyte-derived tauine-chloramines. J. Clin. Lab. Anal. 6(1), 47–53. https://doi.org/10.1002/JCLA.1980060110 (1992).
23. Uchiyama, M. & Mihara, M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86(1), 271–278. https://doi.org/10.1016/0003-2697(79)80342-1 (1978).
24. Cady, C., Evans, M. S. & Brewer, G. J. Age-related differences in NMDA responses in cultured rat hippocampal neurons. J. Neurochem. 62(1), 27–38. https://doi.org/10.1002/JNC.1906201011 (1992).
25. Takahashi, R. H. et al. Oligomerization of alzheimer’s β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24(14), 3592–3599. https://doi.org/10.1523/JNEUROSCI.0767-04 (2004).
26. Reifert, J., Hartung-Cranston, D. A. & Feinstein, S. C. Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. J. Biol. Chem. 286(23), 20797–20811. https://doi.org/10.1074/JBC.M111.323474 (2011).
27. Lecanu, L., Greeson, J. & Papadopoulos, V. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, glosis, and memory impairment in the rat brain. Pharmacology 76(1), 19–33. https://doi.org/10.1159/000198929 (2006).
28. Green, A. J. E. Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer’s disease and Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 28(6), 427–440. https://doi.org/10.1016/S0306-3672(02)701-000-6427-X (2002).
29. Mulder, C. et al. CSF markers related to pathogenetic mechanisms in Alzheimer’s disease. J. Neural Transm. (Vienna, Austria) 109(12), 1491–1498. https://doi.org/10.1007/S00702-002-0763-1 (2002).
35. Nag, S., Tang, F. & Yee, B. K. Chronic intracerebroventricular exposure to beta-amyloid(1–40) impairs object recognition but does not affect spontaneous locomotor activity or sensorimotor gating in the rat. *Exp. Brain Res.* **136**(1), 93–100. https://doi.org/10.1007/S002210000561 (2001).

36. Nag, S., Yee, B. K. & Tang, F. Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1–40). *Brain Res. Bull.* **50**(4), 251–262. https://doi.org/10.1016/S0361-9230(99)00196-3 (1999).

37. Anderson, C. P. et al. Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. *Exp. Cell Res.* **246**(1), 183–192. https://doi.org/10.1006/excr.1998.4303 (1999).

38. Hossain, S., Grande, M., Ahmadkhanov, G. & Pramanik, A. Binding of the Alzheimer amyloid beta-peptide to neuronal cell membranes by fluorescence correlation spectroscopy. *Exp. Mol. Pathol.* **82**(2), 169–174. https://doi.org/10.1016/J. YEXMP. 2007. 01.008 (2007).

39. Rajsacskan, N. S., Devaraj, N. S. & Devaraj, H. Vitamin E prevents buthionine sulfoximine-induced biochemical disorders in the rat. *J. Pharm. Pharmacol.* **56**(1), 91–99. https://doi.org/10.1211/0022357022 430 (2004).

40. Kontush, A. et al. Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. *Free Radic. Biol. Med.* **30**(2), 119–128 (2001).

41. Smith, D. G., Cappai, R. & Barnham, K. J. The redox chemistry of the Alzheimer’s disease amyloid β peptide. *Biochem. Biophys. Acta.* **1768**(8), 1976–1990 (2007).

42. Chen, J. X. & Yan, S. D. Amyloid-beta-induced mitochondrial dysfunction. *J. Alzheimers Dis.* **12**(2), 177–184. https://doi.org/10. 3233/ JAD-2007-12208. PMID:17917162; PMCID:PMC3687359 (2007).

43. Butterfield, D. A., Castegna, A., Lauderback, C. M. & Drake, J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. *Neurobiol. Aging.* **23**, 655–664 (2002).

44. Lovell, M. A., Chengsong, X. & William, R. M. Acrolein is increased in alzheimer’s disease brain and is toxic to primary hippocampal cultures. *Neurobiol. Aging* **22**(2), 187–194 (2001).

**Acknowledgements**

We thank Dr. Arpine Khamperyan for help with the experimental procedures.

**Author contributions**

Study concept: K.Y.; design and methodology: G.K., K.F., H.H., K.Y.; acquisition of data: G. K., K.F., H.H., K.Y.; analysis and interpretation of the data: G.K., K.F., H.H., K.Y.; drafting of the manuscript: G.K., K.F., H.H., K.Y.; critical revision of the manuscript for important intellectual content: K.F., H.H., K.Y.; supervision: K.Y.; procurement of funding: K.Y. All authors have read and agreed to the published version of the manuscript.

**Funding**

This work was supported by the State Committee of Science RA (21T-3A327 and N 10-14/I-1) and the EU-funded H2020 COBRAIN project (857600).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to K.Y.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022